Novel alloxazine analogues: design, synthesis, and antitumour efficacy enhanced by kinase screening, molecular...

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Computational Chemistry

Background:

• Developing novel antitumor agents with enhanced selectivity is crucial for cancer therapy.
• Alloxazine derivatives have shown promise as anticancer compounds.
• Targeting specific tumor cell lines requires precise molecular design.

Purpose of the Study:

• To synthesize and evaluate novel alloxazine analogues for antitumor activity.
• To identify potent alloxazine derivatives with enhanced selectivity for tumor cells.
• To explore structure-activity relationships (SARs) for optimized drug design.

Main Methods:

• In vitro evaluation of growth inhibitory activity against human T-cell acute lymphoblastoid leukemia (CCRF-HSB-2) and human oral epidermoid carcinoma (KB) cell lines.
• Structure-based drug design (SBDD) using GOLD 5.2.2, AutoDock 4.2, and Accelrys Discovery Studio 3.5.
• Prediction of physicochemical properties, pharmacokinetics, drug-likeness, and toxicity using ProTox-II and Swiss ADME.

Main Results:

• Twenty-nine out of 45 synthesized compounds were evaluated.
• Compounds 9e and 10J demonstrated the highest antitumor activity against both CCRF-HSB-2 and KB cell lines.
• Strong correlation observed between IC50 values and AutoDock binding free energy/calculated inhibition (K).

Conclusions:

• Novel alloxazine analogues, particularly compounds 9e and 10J, are potent antitumor agents with enhanced selectivity.
• Computational modeling and SAR analysis provide a basis for further optimization of these compounds.
• The developed alloxazine derivatives show promise as effective antitumor agents with improved selectivity.